Brief: Caribou Biosciences Says Positive Additional Data From CB-010 Allogeneic CAR-T Cell Therapy Phase 1 Antler Trial
10/06/2022 08:04
June 10 (Reuters) - Caribou Biosciences Inc CRBU.O :
* CARIBOU BIOSCIENCES REPORTS POSITIVE ADDITIONAL DATA FROM
CB-010
ALLOGENEIC CAR-T CELL THERAPY PHASE 1 ANTLER TRIAL AT THE
EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2022 HYBRID CONGRESS
* CARIBOU BIOSCIENCES - BASED ON PROMISING INITIAL SAFETY
PROFILE
AND CLINICAL ACTIVITY, ANTLER PHASE 1 TRIAL ENROLLING PATIENTS
AT DOSE LEVEL 2
* ADDITIONAL ANTLER DATA EXPECTED BY YEAR-END 2022
Source text for Eikon: ID:nGNX4ZQ05W
Further company coverage: CRBU.O
((Reuters.Briefs@thomsonreuters.com;))